Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced initial data from the lowest dose cohort of its ongoing Phase 1 study of its P-BCMA-101 CAR-T product in relapsed/refractory multiple myeloma. All three patients remain on study with efficacy seen in all three, including at least one partial response lasting more than 10 weeks at time of data cutoff, and no dose limiting toxicities and no cytokine release syndrome (CRS) of any grade. Additional patients are now being enrolled in the next dose cohort.